Janus kinase inhibition in induction treatment of anti‐MDA5 juvenile dermatomyositis‐associated rapidly progressive interstitial lung disease

Tofacitinib has an important role in pediatric rapidly progressive interstitial lung disease (ILD) associated with juvenile dermatomyositis (JDM), an otherwise potentially fatal condition. It may be useful in induction of remission and can be used safely to maintain remission. Serum ferritin and int...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of rheumatic diseases 2022-02, Vol.25 (2), p.228-231
Hauptverfasser:	Chan Ng, Poh Lin Pauline, Mopur, Archana, Goh, Daniel Yam Thiam, Ramamurthy, Mahesh Babu, Lim, Michael Teik Chung, Lim, Lee Kean, Ooi, Pei Ling, Ang, Elizabeth Youning
Format:	Artikel
Sprache:	eng
Schlagworte:	Child clinical aspects <myositis and related syndromes Dermatomyositis Dermatomyositis - complications Dermatomyositis - drug therapy drug treatment <myositis and related syndromes drug treatment <pediatric rheumatology Ferritin Humans Inflammatory diseases Janus kinase Janus Kinase Inhibitors - administration & dosage Lung diseases Lung Diseases, Interstitial - diagnostic imaging Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - etiology Lung Diseases, Interstitial - pathology Male Musculoskeletal diseases Pediatrics Piperidines - administration & dosage Pyrimidines - administration & dosage Remission Remission (Medicine) Remission Induction - methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Tofacitinib has an important role in pediatric rapidly progressive interstitial lung disease (ILD) associated with juvenile dermatomyositis (JDM), an otherwise potentially fatal condition. It may be useful in induction of remission and can be used safely to maintain remission. Serum ferritin and interleukin‐18 are useful markers for tracking activity and response of JDM‐associated ILD.
ISSN:	1756-1841 1756-185X
DOI:	10.1111/1756-185X.14258